Burwell has faith remaining states will embrace Medicaid expansion

HHS Secretary Sylvia Mathews Burwell spoke to reporters last week about the Affordable Care Act’s 2016 open enrollment figures and the future of healthcare in the U.S.

According to coverage from Kaiser Health News, Burwell said one of her biggest priorities is getting the individual states to expand Medicaid despite concerns around both costs and the program’s effectiveness.

“One goal is encouraging states to accept the health law’s expansion of their Medicaid programs,” Kaiser Health News reported. “Burwell sees that much as a cowboy might in approaching his work: The terrain is a ‘very, very large ranch,’ she said. There are ‘a lot of places to go’ as she works out details for programs and waivers that could give governors flexibility. But there’s also a fence—the program’s statutory requirements—that give her only so much leeway.”

Burwell also said she has faith the remaining states will embrace Medicaid expansion.

“She predicted that economic factors, such as uncompensated care and rising rates of hospital closures in states that have not implemented the law’s Medicaid expansion, will eventually bring all states on board,” Kaiser Health news reported.

Kaiser Health News also cited a HMS figure that stated 4 million enrollees using healthcare.gov this year were enrolling for the first time.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.